1. Lötvall J, Bakke P, Bjermer L, et al. Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FF/VI) in COPD patients. Eur Respir J 2010;24:1013s.
2. Kempsford R, Allen A, Bareille P, et al. The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. Eur Respir J. 2011;38(Suppl. 55):138s.
3. Lötvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012;2:e000370.
4. Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma. Eur Respir J. 2012;40(Suppl. 56):P2092.
5. Boscia JA, Pudi KK, Zvarich MT, et al. Effect of fluticasone furoate (FF)/vilanterol (VI) administered once daily on 24 h pulmonary function in patients with COPD: a randomized, three-way, incomplete block, cross-over study. Am J Resp Crit Care Med. 2012;185(Meeting abstracts):A2939.